Introduction

Steroid hormones sit behind some of the body’s most fundamental processes – stress response, metabolism, blood pressure, reproduction and fertility. When their synthesis or metabolism goes wrong, the result is often a condition with diffuse, wide-ranging symptoms that can take years, multiple specialists and significant cost to properly diagnose.

That’s the problem Intelligent Mass Spec Solutions (IMS Solutions) was spun out to solve. A joint spin-out from the University of Birmingham and Imperial College London, IMS Solutions has built a platform technology that detects unique “steroid fingerprints” in blood and urine, opening the door to faster, more accurate diagnosis of conditions that have historically been difficult and costly to identify – starting with a rare adrenal cancer and the most common hormone disorder in women, with up to 70% of cases undiagnosed.

The Science

IMS Solutions’ platform overcomes a longstanding diagnostic challenge by identifying unique steroid signatures in a patient’s blood or urine, rather than relying on symptom-matching, imaging or process-of-elimination diagnosis.

The technology was initially developed at the University of Birmingham by Professor Wiebke Arlt, a renowned expert in steroid endocrinology, Director of the MRC Laboratory of Medical Sciences, and the first female President of the European Society of Endocrinology.

The first product to reach the clinic will be ACCelerate™, a urine test that discriminates between benign and malignant adrenal tumours, found in 5% of people undergoing a chest or abdomen scan, to identify which patients with Adrenocortical Carcinoma (ACC) actually need surgery. It combines a unique panel of biomarkers with a machine learning algorithm trained on retrospective data, and has already been validated prospectively in a multi-centre study, showing it to be up to four times more accurate than scans alone.

Alongside ACCelerate™, the team is developing the world’s first stratification test for Polyendocrine Metabolic Ovarian Syndrome (PMOS) – a blood test paired with a machine learning algorithm designed for use in primary care to identify which PMOS subgroup a patient falls into and stratify their risk of related conditions like type 2 diabetes and hypertension.

UKI2S Impact

£1.1 million

Seed round led by Midlands Mindforge, with UKI2S as part of the investment syndicate.

£2.1 million

NIHR grant awarded to Imperial College London to fund the regulatory certification and commercialisation of the ACCelerate™ test.

Up to 4x more accurate

Than scans alone - the validated accuracy of the ACCelerate™ test, confirmed in the largest ever adrenal cancer study, spanning over 2,000 patients across 11 countries.

Dr Martin Whitaker, CEO, IMS Solutions, shared:

“IMS Solutions is launching with a strong commercial and scientific team, and a well-advanced roadmap for products that align with current demands from patients, clinicians and healthcare providers.”

Oliver Sexton, Investment Director, Future Planet Capital (managing UKI2S), said:

“UKI2S is backing Intelligent Mass Spec Solutions (IMS Solutions) as it develops novel biomarkers of steroid disorders. Based on the highly cited work of Prof. Arlt the company’s platform rapidly and accurately stratifies patients, avoiding unnecessary surgery and providing clear routes for treatment. As we move ever closer to personalised medicine IMS’ insight helps each patient receive the right treatment.”

UKI2S is proud to be part of the syndicate backing IMS Solutions as it brings world-leading steroid endocrinology research out of the University of Birmingham and Imperial College London and into clinical use. Conditions rooted in disordered steroid hormone metabolism – from Adrenocortical Carcinoma to PMOS, are notoriously difficult to diagnose, and women’s health conditions in particular have long been underfunded relative to the number of people they affect. IMS Solutions’ steroid fingerprint technology offers a faster, more accurate route to diagnosis for both, starting with ACCelerate™, which is on track for UK launch by 2029, and a first-of-its-kind PMOS stratification test now in clinical validation.

Backing IMS Solutions alongside Midlands Mindforge, SFC Capital, NG Bio, British Business Bank and other private investors reflects exactly the kind of deep-tech, university-rooted pipeline UKI2S exists to support: rigorous, clinically validated science, backed by investors able to help it reach patients and the NHS at scale.

IMS Solutions is a strong example of what happens when world-class UK research is given the funding and commercial support to reach the clinic. With a rapid, accurate diagnostic already validated in one of the largest studies of its kind, and a genuinely novel test for a widely underdiagnosed condition close behind it, IMS Solutions is set to change how steroid hormone conditions are diagnosed and treated, and UKI2S is proud to be backing the team as they work to show the test can run reliably in existing NHS labs.

Get your innovation off the ground

Check to see if you are eligible for UKI2S funding

UKI2S
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.